Ecke TH - Search Results

1

TP53 gene mutations as an independent marker for urinary bladder cancer progression.

Ecke TH, Sachs MD, Lenk SV, Loening SA, Schlechte HH. Ecke TH, et al. Int J Mol Med. 2008 May;21(5):655-61. Int J Mol Med. 2008. PMID: 18425359

2

Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.

Ecke TH, Lenk SV, Schlechte HH, Loening SA. Ecke TH, et al. Anticancer Res. 2003 Mar-Apr;23(2A):957-62. Anticancer Res. 2003. PMID: 12820330

3

Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.

Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA. Ecke TH, et al. Anticancer Res. 2005 Jan-Feb;25(1B):635-41. Anticancer Res. 2005. PMID: 15816639 Free article.

4

TP53 mutation in prostate needle biopsies--comparison with patients follow-up.

Ecke TH, Schlechte HH, Hübsch A, Lenk SV, Schiemenz K, Rudolph BD, Miller K. Ecke TH, et al. Anticancer Res. 2007 Nov-Dec;27(6B):4143-8. Anticancer Res. 2007. PMID: 18225585 Free article.

5

Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.

Ecke TH, Schlechte HH, Gunia S, Lenk SV, Loening SA. Ecke TH, et al. Urol Oncol. 2008 Sep-Oct;26(5):470-3. doi: 10.1016/j.urolonc.2007.12.005. Epub 2008 Mar 4. Urol Oncol. 2008. PMID: 18367114

6

Focus on urinary bladder cancer markers: a review.

Ecke TH. Ecke TH. Minerva Urol Nefrol. 2008 Dec;60(4):237-46. Minerva Urol Nefrol. 2008. PMID: 18923360 Review.

7

TP53 gene mutations in prostate cancer progression.

Ecke TH, Schlechte HH, Schiemenz K, Sachs MD, Lenk SV, Rudolph BD, Loening SA. Ecke TH, et al. Anticancer Res. 2010 May;30(5):1579-86. Anticancer Res. 2010. PMID: 20592345

8

Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer.

Ecke TH, Arndt C, Stephan C, Hallmann S, Lux O, Otto T, Ruttloff J, Gerullis H. Ecke TH, et al. Anticancer Res. 2015 May;35(5):2651-5. Anticancer Res. 2015. PMID: 25964541

9

Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer.

Ecke TH. Ecke TH. Adv Exp Med Biol. 2015;867:293-316. doi: 10.1007/978-94-017-7215-0_18. Adv Exp Med Biol. 2015. PMID: 26530373 Review.

10

Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.

Ecke TH, Huang-Tiel HJ, Golka K, Selinski S, Geis BC, Koswig S, Bathe K, Hallmann S, Gerullis H. Ecke TH, et al. Int J Mol Sci. 2016 Nov 10;17(11):1879. doi: 10.3390/ijms17111879. Int J Mol Sci. 2016. PMID: 27834929 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

119 results

Search Page

Filters